| BRISTOL-MEYERS-SQUIBB |
BRISTOL-MEYERS-SQUIBB |
90%
|
Bristol Meyers Squibb (BMS) and Sandoz account for more than 10% of group revenues, individually (as in 2024). |
| SANDOZ |
SANDOZ |
90%
|
Bristol Meyers Squibb (BMS) and Sandoz account for more than 10% of group revenues, individually (as in 2024). |
| EVOTEC-GROUP |
EVOTEC-GROUP |
85%
|
Total revenue from contracts with customers 599,086 183,431 782,517 Timing of revenue recognition At a point in time 83,157 44,123 127,280 Over a period of time 515,929 139,308 655,237 Total re… |
| MANU |
Manchester |
72%
|
Reciprocal relationship from MANU graph: Reciprocal relationship from EVO graph: Reciprocal relationship from MANU graph: Reciprocal relationship from EVO graph: Reciprocal relationship from MANU gra… |
| MANU |
Manchester |
72%
|
s expected to be approximately 130,000 square feet and will house approximately 200 employees at full capacity. The site, which will be able to produce on a large enough scale to meet most of our com… |
| RXRX |
Recursion Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from RXRX graph: Reciprocal relationship from EVO graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from EVO graph: Reciprocal relationship from RXRX gra… |
| RXRX |
Recursion Pharmaceuticals, Inc. |
72%
|
o our revenue was 74 and 109 in 2025 and 2024, respectively (2023:102). Evotec’s largest three customers by revenue collectively accounted for 43% of revenues from contracts with customers in 2025. I… |
| SNYNF |
Sanofi |
72%
|
s expected to be approximately 130,000 square feet and will house approximately 200 employees at full capacity. The site, which will be able to produce on a large enough scale to meet most of our com… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVO graph: s expected to be approximately 130,000 square feet and will house approximately 200 employees at full capacity. The s… |
| ADJUSTED-EBITDA-ADJUSTED-GROUP |
ADJUSTED-EBITDA-ADJUSTED-GROUP |
62%
|
es to assess the progress of our business, make decisions about where to allocate time and investments and assess the near-term and longer-term performance of our business. The measures set forth bel… |
| ADJUSTED-EBITDA-EVOTEC-GROUP |
ADJUSTED-EBITDA-EVOTEC-GROUP |
62%
|
o the relevant date. 100% of the key performance indicator “Group Revenue” is achieved (“Target Group Revenue”) when the cumulative growth in Group revenue of Evotec SE in the performance measurement… |
| ADMINISTRATIVE-EXPENSES-THE-GROUP |
ADMINISTRATIVE-EXPENSES-THE-GROUP |
62%
|
ring program, in accordance with IAS 37. Types of costs included are employee termination benefits, contract termination costs, consulting and legal fees directly associated with the program, as well… |
| AEOVIAN-PHARMACEUTICALS-INC |
AEOVIAN-PHARMACEUTICALS-INC |
62%
|
These companies may originate from our Biomedical Research, Innovation & Development Generation Efficiency (BRIDGEs) program, where Evotec collaborates with academic institutions to facilitate the ac… |
| ANANKE-THERAPEUTICS-INC |
ANANKE-THERAPEUTICS-INC |
62%
|
These companies may originate from our Biomedical Research, Innovation & Development Generation Efficiency (BRIDGEs) program, where Evotec collaborates with academic institutions to facilitate the ac… |
| APTUIT-OXFORD-LTD |
APTUIT-OXFORD-LTD |
62%
|
Past due 1-30 days 25,837 24,704 Risk provision 1-30 days ( 170 ) ( 67 ) Past due 31-120 days 12,688 6,559 Risk provision 31-120 days ( 280 ) ( 469 ) More than 120 days 8,582 6,109 Risk provision mor… |
| AUTOBAHN-LABS-LLC |
AUTOBAHN-LABS-LLC |
62%
|
These companies may originate from our Biomedical Research, Innovation & Development Generation Efficiency (BRIDGEs) program, where Evotec collaborates with academic institutions to facilitate the ac… |
| BDO-AG |
BDO-AG |
62%
|
lestones is highly probable, and (iv) evaluating the appropriateness of the over-time revenue recognition vs. point in time for complex contracts with customers. ● Assessing the reasonableness of ove… |
| BLACKSMITH-MEDICINES-INC |
BLACKSMITH-MEDICINES-INC |
62%
|
These companies may originate from our Biomedical Research, Innovation & Development Generation Efficiency (BRIDGEs) program, where Evotec collaborates with academic institutions to facilitate the ac… |
| BREAKPOINT-THERAPEUTICS-GMBH |
BREAKPOINT-THERAPEUTICS-GMBH |
62%
|
These companies may originate from our Biomedical Research, Innovation & Development Generation Efficiency (BRIDGEs) program, where Evotec collaborates with academic institutions to facilitate the ac… |
| CAJAL-NEUROSCIENCE-INC |
CAJAL-NEUROSCIENCE-INC |
62%
|
These companies may originate from our Biomedical Research, Innovation & Development Generation Efficiency (BRIDGEs) program, where Evotec collaborates with academic institutions to facilitate the ac… |
| CENTAURI-THERAPEUTICS-GMBH |
CENTAURI-THERAPEUTICS-GMBH |
62%
|
creased interest rates for investments of Evotec’s liquidity on short term investments in particular in EUR and USD. Interest Expense Interest expense decreased by €1.4 million, or (10.7)%, from €13.… |
| CENTAURI-THERAPEUTICS-LTD |
CENTAURI-THERAPEUTICS-LTD |
62%
|
r 5, 2025. The agreement includes approximately USD 350 m in cash for the JEB manufacturing site in Toulouse and upfront technology license fees for JEB’s complete technology stack. In addition, Evot… |
| CONTRIBUTIONS-THE-GROUP |
CONTRIBUTIONS-THE-GROUP |
62%
|
ayments on service obligations. Revenue from contributions Revenue Recognition from Contributions The Group receives private contributions for which the existence of an adequate exchange transaction … |
| CUMULATIVE-GROUP |
CUMULATIVE-GROUP |
62%
|
o the relevant date. 100% of the key performance indicator “Group Revenue” is achieved (“Target Group Revenue”) when the cumulative growth in Group revenue of Evotec SE in the performance measurement… |
| CUREXSYS-GMBH |
CUREXSYS-GMBH |
62%
|
creased interest rates for investments of Evotec’s liquidity on short term investments in particular in EUR and USD. Interest Expense Interest expense decreased by €1.4 million, or (10.7)%, from €13.… |
| DARK-BLUE-THERAPEUTICS-LTD |
DARK-BLUE-THERAPEUTICS-LTD |
62%
|
o our revenue was 74 and 109 in 2025 and 2024, respectively (2023:102). Evotec’s largest three customers by revenue collectively accounted for 43% of revenues from contracts with customers in 2025. I… |
| EQUITY-HOLDINGS |
EQUITY-HOLDINGS |
62%
|
These companies may originate from our Biomedical Research, Innovation & Development Generation Efficiency (BRIDGEs) program, where Evotec collaborates with academic institutions to facilitate the ac… |
| EVT-EXECUTE-EVT-INNOVATE-EVOTEC-GROUP |
EVT-EXECUTE-EVT-INNOVATE-EVOTEC-GROUP |
62%
|
time 491,445 186,950 678,395 Total revenue from contracts with customers 536,167 204,730 740,897 Revenue from contributions 10,551 — 10,551 Total Revenue 546,718 204,730 751,448 *) Compri… |
| EVT-INNOVATE-EVOTEC-GROUP |
EVT-INNOVATE-EVOTEC-GROUP |
62%
|
EVT Innovate Evotec Group Revenues from contracts with customers Fee for service and FTE-based research payments 472,205 254,724 726,929 Recharges* 30,496 7,065 37,561 Compound access fees 1,283 776 … |
| IKB-DEUTSCHE-INDUSTRIEBANK-AG |
IKB-DEUTSCHE-INDUSTRIEBANK-AG |
62%
|
tomers Who Contributed More Than €1 million to Our Revenue The number of customers who contributed more than €1 million to our revenue was 102 and 118 in 2023 and 2022, respectively. Evotec’s largest… |
